Interferon antibodies: do they alter the beneficial effects of beta-interferon upon relapse rate in multiple sclerosis?

The IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomised, double-blind, placebo-controlled trial . Neurology 1993; 43: 655-661 .

Jacobs LD , Cookfair DL , Ruddick RA , Herndon RM , Richert JR , Slazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing remitting multiple sclerosis . Ann Neurol 1996; 39: 285-294 .

PRISMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group . Randomised double-blind placebo-controlled study of inter-feron b-1a in relapsing/remitting multiple sclerosis . Lancet 1998; 352: 1498-1504 .

European Study Group on Interferon b-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon b-1b in treatment of secondary progressive multiple sclerosis . Lancet 1998; 352: 1491-1497 .

SPECTRIMS (Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon b-1a in Multiple Sclerosis) Study Group . Randomised controlled trial of Interferon b-1a in secondary progressive multiple sclerosis: clinical results . Neurology 2001; 56: 1496-1504 .

Panitch H , Goodwin DS , Francis G , Chang P , Coyle PK , O’Cooner P et al. Randomized, comparative study of inter-feron b-1a treatment regimens in MS. The EVIDENCE Trial . Neurology 2002; 59: 1496-1506 .

The Once Weekly Interferon for MS Study Group (OWIMS) . Evidence of interferon b-1a dose response in relapsing-remitting MS . Neurology 1999; 53: 679-686 .

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group . Neutralizing antibodies during treatment of multiple sclerosis with inter-feron beta-1b: experience during the first three years . Neurology 1996; 47: 889-894 .

Rudick RA , Simonian NA , Alam JA , Campion M , Scaramucci JO , Jones W et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis . Neurology 1998; 50: 1266-1272 .

Sorensen PS , Ross C , Clemmesen KM , Bendzen K , Frederifsen JL et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis . Lancet 2003; 362: 1184-1191 .

Bertolotto A , Gilli F , Sala A , Capobianco M , Malucchi S , Milano E et al. Persistent neutralizing antibodies abolish the interferon b bioavailability in MS patients . Neurology 2003; 60: 634-639 .

Polman C , Kappos L , White R , Dahlke F , Beckmann K , Pozzilli C et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon b-1b . Neurology 2003; 60: 37-43 .

Wolinsky JS , Toyka KV , Kappos L , Grossberg SE. Interferon-beta antibodies: implications for treatment of MS . Lancet 2003; 2: 528-528 .

Petkau AJ , White RA , Ebers BGC , Reder AT , Sibley WA , Lublin FD et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing -remitting multiple sclerosis . Multiple Sclerosis 2004; 10: 126-138 .

Pozzilli C , Antonini G , Bagnato F , Mainero C , Tomassini V , Onesti E et al. Monthly corticosteroids decrease neutralizing antibodies to IFN b1b: a randomized trial in multiple sclerosis . J Neurol 2002; 249: 50-56 .

Yudkin PL , Ellison GW , Ghezzi A , Goodkin DE , Hughes RAC , McPherson K et al. Overview of azathioprine treatment in multiple sclerosis . Lancet 1991; 338: 1051-1055 .

Hartung HP , Gonsette R , Konig N , Kwiecinski H , Guseo A , Morrisey SP et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial . Lancet 2002; 360: 2018-2025 .

Bornstein MB , Miller A , Slagle S , Wiezman M , Crystal H , Drexler E et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis . N Engl J Med 1987; 317: 408-414 .

Johnson KP , Brooks BR , Cohen JA , Ford CC , Goldstein J , Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing -remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial . Neurology 1995; 45: 1268-1276 .